Media coverage about BIOLINERX Ltd/S (NASDAQ:BLRX) has been trending positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BIOLINERX Ltd/S earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.80042450557 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- BIOLINERX Ltd/S (BLRX) vs. Vistagen Therapeutics (VTGN) Critical Survey (americanbankingnews.com)
- Oppenheimer reiterates Outperform rating on BioLineRx after positive data from GENISIS study of BL-8040 (proactiveinvestors.com)
- BIOLINERX Ltd/S (BLRX) Set to Announce Quarterly Earnings on Monday (americanbankingnews.com)
- BIOLINERX Ltd/S (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization (finance.yahoo.com)
BIOLINERX Ltd/S remained flat at $$0.88 during mid-day trading on Friday, Marketbeat.com reports. 114,462 shares of the company’s stock traded hands, compared to its average volume of 196,712. The company has a market capitalization of $93.31 million, a P/E ratio of -3.26 and a beta of 0.50. BIOLINERX Ltd/S has a 1-year low of $0.78 and a 1-year high of $1.34.
BLRX has been the subject of several recent research reports. HC Wainwright set a $4.00 price target on shares of BIOLINERX Ltd/S and gave the stock a “buy” rating in a research note on Tuesday, August 7th. ValuEngine raised shares of BIOLINERX Ltd/S from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised shares of BIOLINERX Ltd/S from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. Finally, MED initiated coverage on shares of BIOLINERX Ltd/S in a research note on Wednesday, August 1st. They issued a “market perform” rating for the company. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. BIOLINERX Ltd/S has a consensus rating of “Buy” and a consensus price target of $2.75.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Recommended Story: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.